[1] Reich D S, Lucchinetti C F, Calabresi P A. Multiple sclerosis [J]. N Engl J Med, 2018, 378(2): 169-180. [2] Olsson T, Barcellos L F, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis [J]. Nat Rev Neurol, 2017, 13(1): 25-36. [3] Marcus R. What is multiple sclerosis? [J]. JAMA, 2022, 328(20): 2078. [4] The L N. Multiple sclerosis under the spotlight [J]. Lancet Neurol, 2021, 20(7): 497. [5] Correale J, Marrodan M, Ysrraelit M C. Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis [J]. Biomedicines, 2019, 7(1): 7010014. [6] Saab A S, Nave K. Myelin dynamics: protecting and shaping neuronal functions [J]. Curr Opin Neurobiol, 2017, 47: 104-112. [7] Schirmer L, Mobius W, Zhao C, et al. Oligodendrocyte-encoded Kir4.1 function is required for axonal integrity [J]. Elife, 2018(7): e36428-e36428. [8] Yang C, Wang Y, Hua M, et al. Aryl hydrocarbon receptor: from pathogenesis to therapeutic targets in aging-related tissue fibrosis [J]. Ageing Res Rev, 2022, 79: 101662. [9] Zhang W, Xie H Q, Li Y, et al. The aryl hydrocarbon receptor: a predominant mediator for the toxicity of emerging dioxin-like compounds [J]. J Hazard Mater, 2022, 426: 128084. [10] Wang Y, Sun J, Zhu K, et al. Microglial aryl hydrocarbon receptor enhances phagocytic function via SYK and promotes remyelination in the cuprizone mouse model of demyelination [J]. Journal of Neuroinflammation, 2023, 20(1): 83. [11] Sen M K, Mahns D A, Coorssen J R, et al. Behavioural phenotypes in the cuprizone model of central nervous system demyelination [J]. Neurosci Biobehav Rev, 2019, 107: 23-46. [12] Vega-Riquer J M, Mendez-Victoriano G, Morales-Luckie R A, et al. Five decades of cuprizone, an updated model to replicate demyelinating diseases [J]. Curr Neuropharmacol, 2019, 17(2): 129-141. [13] Zhan J, Mann T, Joost S, et al. The cuprizone model: dos and do nots [J]. Cells, 2020, 9(4): 9040843. [14] Ludwin S K. Central nervous system demyelination and remyelination in the mouse: an ultrastructural study of cuprizone toxicity [J]. Lab Invest, 1978, 39(6): 597-612. [15] Zhu K, Sun J, Kang Z, et al. Electroacupuncture promotes remyelination after cuprizone treatment by enhancing myelin debris clearance [J]. Front Neurosci, 2016, 10: 613. [16] Neumann H, Kotter M R, Franklin R J M. Debris clearance by microglia: an essential link between degeneration and regeneration [J]. Brain, 2009, 132: 288-295. [17] Xia Y. Advanced acupuncture research: from bench to bedside [M]. Cham: Springer, 2022. [18] Ding Y, Shi X. Controlled research on multiple sclerosis treated with electroacupuncture and acupoint injection [J]. Chinese Acupuncture & Moxibustion, 2013, 33(9): 793-795. [19] Wang C, Chen Z, Wang L, et al. Relapsing-remitting multiple sclerosis at remission stage treated with acupuncture: a randomized controlled trial [J]. Chinese Acupuncture & Moxibustion, 2017, 37(6): 576-580. [20] Lloyd A F, Miron V E. The pro-remyelination properties of microglia in the central nervous system [J]. Nat Rev Neurol, 2019, 15(8): 447-458. [21] Berghoff S A, Spieth L, Sun T, et al. Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis [J]. Nat Neurosci, 2021, 24(1): 47-60. [22] Patani R, Balaratnam M, Vora A, et al. Remyelination can be extensive in multiple sclerosis despite a long disease course [J]. Neuropathol Appl Neurobiol, 2007, 33(3): 277-287. [23] Voss E V, Skuljec J, Gudi V, et al. Characterisation of microglia during de- and remyelination: can they create a repair promoting environment? [J]. Neurobiol Dis, 2012, 45(1): 519-528. [24] Masuda T, Sankowski R, Staszewski O, et al. Author correction: spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution [J]. Nature, 2019, 568(7751): E4. [25] Franklin R J M, Ffrench-Constant C. Regenerating CNS myelin: from mechanisms to experimental medicines [J]. Nat Rev Neurosci, 2017, 18(12): 753-769. [26] Stangel M, Kuhlmann T, Matthews P M, et al. Achievements and obstacles of remyelinating therapies in multiple sclerosis [J]. Nat Rev Neurol, 2017, 13(12): 742-754. [27] Rawji K S, Kappen J, Tang W, et al. Deficient surveillance and phagocytic activity of myeloid cells within demyelinated lesions in aging mice visualized by ex vivo live multiphoton imaging [J]. J Neurosci, 2018, 38(8): 1973-1988. [28] Healy L M, Perron G, Won S, et al. MerTK is a functional regulator of myelin phagocytosis by human myeloid cells [J]. J Immunol, 2016, 196(8): 3375-3384. [29] Zou Z, Sun J, Kang Z, et al. Tyrosine kinase receptors Axl and MerTK mediate the beneficial effect of electroacupuncture in a cuprizone-induced demyelinating model [J]. Evid Based Complement Alternat Med, 2020(7): 3205176. [30] Tohyama Y, Yamamura H. Protein tyrosine kinase, Syk: a key player in phagocytic cells [J]. J Biochem, 2009, 145(3): 267-273. [31] Berton G, MocSai A, Lowell C A. Src and Syk kinases: key regulators of phagocytic cell activation [J]. Trends Immunol, 2005, 26(4): 208-214. [32] Jakus Z, Simon E, Balazs B, et al. Genetic deficiency of Syk protects mice from autoantibodyinduced arthritis [J]. Arthritis Rheum, 2010, 62(7): 1899-1910. [33] Podolanczuk A, Lazarus A H, Crow A R, et al. Of Mice and Men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk [J]. Blood, 2009, 113(14): 3154-3160. [34] Ennerfelt H, Frost E L, Shapiro D A, et al. SYK coordinates neuroprotective microglial responses in neurodegenerative disease [J]. Cell, 2022, 185(22): 4135-4152. |